A Study to Assess the Pharmacokinetics of Rifaximin Soluble Solid Dispersion (SSD) Formulation in Adult Subjects with Impaired Hepatic Function

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505434-98-00

Acronym

RNPK1018

Enrollment

Registered

2023-10-13

Start date

2023-11-13

Completion date

2024-05-24

Last updated

2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatic impairment.

None listed

Sex/Gender

All

Age

18 Years to No maximum

Hungary

None listed

Source: EU CTIS · Data processed: Feb 4, 2026